Anupam Rasayan operates in the specialty chemicals niche of complex fluorination and custom synthesis, serving multinational innovators across agrochemicals, pharmaceuticals, and performance materials. In FY26, standalone revenue mix was agrochemicals at 55%, pharma at 20%, and performance materials at 18%, a deliberate shift away from the 76% agro dependence seen in FY22. The company is acquiring and integrating assets to create an end-to-end platform, with Tanfac supplying critical raw materials, Anupam providing Indian cost-efficient synthesis, and the newly acquired Jayhawk adding a US onshore manufacturing site. Standalone EBITDA margin sits around 23-24%, while Jayhawk runs near 19-20%, making the consolidated margin mix a central analytical focus. This is not a commodity bulk manufacturer; the high specific chemistry and validated customer base suggest a niche with few meaningful global peers.
The economics persist because of long qualification cycles and critical switching costs, not scale alone. Management highlighted on the December 2025 call that semiconductor and aviation customer qualifications take 5-7 years; Jayhawk already holds validated products and approved US customers, effectively shortcutting Anupam's entry into those segments by a full cycle. Backward integration via Tanfac locks in hydrofluoric acid and potassium fluoride inputs, creating a cost advantage that is hard to replicate. The pipeline of over 65 molecules across pharma and polymer stages, combined with cumulative signed LOIs representing roughly INR18,000 crores of potential business over ten years, points to durable demand visibility. Entry barriers are compounded by the proprietary flow chemistry used to commercialize ETFE, a first globally, which provides both safety and cost leadership.
The inflection is now, as the Bliss GVS acquisition closes by mid-September 2026 and Jayhawk is already consolidated. Looking 18-24 months forward, the combined platform of Anupam, Tanfac, Jayhawk, and Bliss is expected to exceed INR4,000 crores in pro forma revenue with EBITDA around INR834 crores. The single biggest lever is capacity utilization: Bliss currently runs at only 30% and management targets 60-70% within two to three years, while Jayhawk's vast site is only 15-20% utilized. In FY27, guidance calls for 20-25% organic standalone growth plus an incremental 10-15% from Jayhawk, and the standalone business can reach a peak revenue of INR3,500 crores on its existing gross block without major new capex. Working capital days, historically a drag, are guided to fall below 200 and ideally towards 180 by the end of FY27, releasing cash as the higher-margin pharma and polymer mix takes hold.
Management has a verified pattern of over-delivery. They guided FY26 revenue growth of over 30 percent, and H1 FY26 delivered 122% year-on-year growth. Working capital days compressed from 409 to 247 in that same period, and order book conversion matched targets. The guidance for EBITDA margins to normalize at 25% was met in Q3 FY26 at that level. On capital allocation, the acquisitions are funded without heavy dilution: Jayhawk used debt plus INR110 crores in non-voting Class B shares, while the Bliss transaction will use INR300 crores in NCDs and quasi-equity. Going forward, capital expenditure is limited to INR50-75 crores annually for maintenance, preserving balance sheet flexibility while the combined entity's operating cash flow improves. The stated commitment to conclude the Bliss transaction by September and to maintain consolidated EBITDA margins between 22-24% forms the walk-talk baseline for the next two years.
The quantified earnings path depends on converting the INR14,000 crore order book into revenue, implying roughly INR2,200 crores of incremental annual income on a seven-year average basis. With FY26 operating cash flow already at INR334 crores and net debt expected at INR1,400-1,500 crores post-Bliss, interest coverage remains manageable if growth holds. The kill shot for this thesis is integration slippage: if Bliss utilization fails to ramp from 30% towards 60-70% due to regulatory delays or if Jayhawk synergies from cross-selling with Tanfac do not materialize, the pro forma EBITDA of INR834 crores is at risk. The tension between a rising gross margin and potential PAT suppression from higher depreciation and interest is structural rather than operational, resolved only if working capital release and volume growth outpace the incremental balance sheet costs. The single most important watchpoint by mid-FY28 is the blended EBITDA margin of the combined platform sustaining the 22-24% band while the new capacities reach their utilization targets.
companyname: Anupam Rasayan India Limited ticker: ANURAS sector: Specialty Chemicals Anupam Rasayan India Limited is a custom synthesis and specialty chemicals manufacturer headquartered in Surat, Gujarat, founded in 1984. The company performs complex, multi-step chemical synthesis for a global client base, and sells its output across four end-markets: agrochemicals, pharmaceuticals, performance materials, and personal care. On a standalone basis in FY26, the segment mix was 55% agrochemicals, ...
Read the full report →margin expansion, new product segment, order book surge, acquisition inorganic
FY27-28 revenue growth guided at 20-30% CAGR driven by Pharma and Polymer segments expansion
Guidance maintainedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Anupam Rasayan India Limited and 4,900+ companies.
5-day free pass. No card required.